Bellevue Group AG Cuts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bellevue Group AG decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 39.9% during the first quarter, Holdings Channel.com reports. The fund owned 4,810 shares of the company’s stock after selling 3,190 shares during the period. Bellevue Group AG’s holdings in Krystal Biotech were worth $856,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $127,000. Pier 88 Investment Partners LLC acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $145,000. Lazard Asset Management LLC raised its stake in shares of Krystal Biotech by 27.5% during the 1st quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after buying an additional 282 shares during the period. Headlands Technologies LLC purchased a new position in Krystal Biotech in the 1st quarter valued at $291,000. Finally, Capstone Investment Advisors LLC purchased a new position in Krystal Biotech in the 4th quarter valued at $303,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a report on Monday, May 6th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $177.63.

Krystal Biotech Stock Performance

Shares of KRYS traded down $7.92 during midday trading on Monday, hitting $205.74. The company had a trading volume of 81,788 shares, compared to its average volume of 378,259. The company’s 50-day simple moving average is $181.53 and its 200-day simple moving average is $161.20. The firm has a market capitalization of $5.88 billion, a P/E ratio of 114.26 and a beta of 0.84. Krystal Biotech, Inc. has a 1 year low of $93.95 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analysts’ expectations of $47.37 million. The firm’s revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.76) EPS. Equities analysts predict that Krystal Biotech, Inc. will post 2.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, Director Julian S. Gangolli sold 20,000 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).